Neuland management has repeatedly said that the CMS business can be a but lumpy and should not be viewed QoQ. On a broader note, Unit 3 utilization is improving and you can see the progress of molecules advancing towards commercialization in the last six month. I’ll review the position next after Q4 results.
| Subscribe To Our Free Newsletter |
